MRMD just reported Q1 2026 results after the close on May 13, beating the revenue consensus estimate of $38.75M with $39.48M in sales. The earnings call follows on May 14. That puts the stock at an interesting juncture — down nearly 10% on the week at $0.083, yet carrying a small revenue beat into the discussion investors have been waiting for.
The short interest story is almost a non-event. At roughly 0.004% of the free float, short positioning is negligible by any measure. What makes the week's data worth a second look is the volatility in that number itself: estimated short shares fell 72% over the past week alone, collapsing from around 81,000 shares to just 14,000. That kind of daily noise at these tiny absolute levels reflects little more than rounding and settlement artefacts rather than any directional conviction. Borrow costs have actually drifted lower over May — from nearly 10% at the start of the month to around 8% now — and availability is, for practical purposes, unlimited. There is no meaningful short squeeze dynamic at work here.
The stock's factor profile is more interesting than the short data suggests. MRMD ranks in the 91st percentile on days-to-cover, reflecting the thin daily volume common to OTC micro-caps rather than an actual borrow squeeze. The EPS surprise score — 75th percentile — aligns with tonight's print, where adjusted EPS of -$0.01 came in line and revenue cleared estimates. The short score itself is a modest 30.8, well below levels that would signal elevated bearish activity. One data point worth noting: the ORTEX short score has been essentially flat-to-rising in early May (from 29.4 on May 11 to 30.8 today), a mild uptick, though at these levels it reads more as background noise than a directional signal.
Insider activity over the past 90 days follows a consistent pattern of stock-award grants immediately followed by small sell transactions — the CEO Jon Levine received 75,000 shares on May 7 and sold roughly 26,000 the same day at $0.087, a value of just over $2,200. The COO and Chief Commercial Officer followed the same award-then-sell pattern in March and April. The net 90-day insider position is nominally positive at around 78,000 shares, but the value in dollar terms — under $6,600 — is effectively zero. This is routine compensation plan mechanics, not a signal of insider conviction in either direction.
Analyst coverage is limited and stale. The most recent coverage initiation in the ORTEX data dates to 2023, and the mean price target of $0.25 is mathematically plausible relative to the $0.083 current price but has not been updated recently enough to carry weight. No bellwether firm has weighed in within the past six months. The Street is, for now, largely watching from a distance.
The closest peers all traded lower on the week — TRUL fell 16%, CL dropped 13%, and TSND was off nearly 8%, reflecting sector-wide pressure on cannabis names. Against that backdrop MRMD's 10% weekly decline is in line rather than idiosyncratic, and the Q4 2025 print — sales of $41.65M, a net loss that narrowed year-on-year — established a trajectory the Q1 beat now extends. The May 14 earnings call, and any commentary on Q2 outlook or the cannabis regulatory backdrop, is what shapes the next move.
See the live data behind this article on ORTEX.
Open MRMD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
